Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Dermatol Clin. 2011 Jan;29(1):1-8. doi: 10.1016/j.det.2010.09.006.

Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.

Author information

  • 1Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. douglas.walsh@afrims.org

Abstract

Buruli ulcer (BU), caused by the environmental organism Mycobacterium ulcerans and characterized by necrotizing skin and bone lesions, poses important public health issues as the third most common mycobacterial infection in humans. Pathogenesis of M ulcerans is mediated by mycolactone, a necrotizing immunosuppressive toxin. First-line therapy for BU is rifampin plus streptomycin, sometimes with surgery. New insights into the pathogenesis of BU should improve control strategies.

Published by Elsevier Inc.

PMID:
21095521
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk